Paradigm Biopharmaceuticals Limited Stock
Equities
PAR
AU000000PAR5
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.25 AUD | -3.85% | -10.71% | -41.18% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 87.59M 131M |
---|---|---|---|---|---|
Net income 2024 * | -72M -108M | Net income 2025 * | -30M -45M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.24
x | P/E ratio 2025 * |
-4.03
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.55% |
1 day | -3.85% | ||
1 week | -10.71% | ||
Current month | -7.41% | ||
1 month | -12.28% | ||
3 months | -27.54% | ||
6 months | -36.71% | ||
Current year | -41.18% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Abby Macnish
DFI | Director of Finance/CFO | - | 22-08-29 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Amos Meltzer
BRD | Director/Board Member | 58 | 20-12-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 0.25 | -3.85% | 855,570 |
24-05-20 | 0.26 | -3.70% | 754,085 |
24-05-17 | 0.27 | -3.57% | 460,151 |
24-05-16 | 0.28 | -1.75% | 296,831 |
24-05-15 | 0.285 | +1.79% | 450,217 |
Delayed Quote Australian S.E., May 21, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.18% | 60.84M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- PAR Stock